0000000000760830
AUTHOR
Mikel Basterretxea
Associations of maternal circulating 25-hydroxyvitamin D3 concentration with pregnancy and birth outcomes
Objective To investigate the association of maternal circulating 25-hydroxyvitamin D3 [25(OH)D3] concentration with pregnancy and birth outcomes. Design Prospective cohort study. Setting Four geographical areas of Spain, 2003–2008. Population Of 2382 mother–child pairs participating in the INfancia y Medio Ambiente (INMA) Project. Methods Maternal circulating 25(OH)D3 concentration was measured in pregnancy (mean [SD] 13.5 [2.2] weeks of gestation). We tested associations of maternal 25(OH)D3 concentration with pregnancy and birth outcomes. Main outcome measures Gestational diabetes mellitus (GDM), preterm delivery, caesarean section, fetal growth restriction (FGR) and small-for-gestational…
Prenatal exposure to perfluoroalkyl substances, immune-related outcomes, and lung function in children from a Spanish birth cohort study.
Background: Prenatal exposure to perfluoroalkyl substances (PFASs) has been associated with impaired immune and respiratory health during childhood but the evidence is inconsistent and limited for lung function. We studied the association between prenatal PFASs exposure and immune and respiratory health, including lung function, up to age 7 years in the Spanish INMA birth cohort study. Methods: We assessed four PFASs in maternal plasma samples collected during the 1st trimester of pregnancy (years: 2003-2008): perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorononanoate (PFNA). Mothers reported the occurrence (yes/no) of lower respir…
Prenatal exposure to perfluoroalkyl substances and immune and respiratory outcomes
Prenatal exposure to perfluoroalkyl substances (PFAS) may be associated with impaired immune and respiratory health during childhood but the evidence is scarce and inconsistent. We studied the association between prenatal PFAS exposure and immune and respiratory health up to age 7 years in the Spanish INMA birth cohort (n=1188). We assessed perfluorohexane sulfonate (PFHxS), perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorononanoate (PFNA) in maternal plasma samples. Mothers reported the occurrence (yes/no) of chest infections, lower respiratory tract infections, wheezing, asthma, and eczema in the previous 12 months at 1.5 and 4 years of the child and at 7 years. A…